As of 2 February 2011, Kancera AB's future subsidiary iNovacia AB has sold its entire holding of 864,000 shares in Kancera AB at the price of SEK 7 per share. This means that the Kancera Group will receive around a further SEK 6 million. The divestment of shares entails no dilution.
The listing of Kancera's shares on NASDAQ OMX First North is expected to take place in February 2011. The share's short name or ticker is KAN.
About Kancera AB (publ)
Kancera AB is a biotechnology company which focuses on new and effective drugs for treating leukaemia and solid tumours.
For further information, contact
Dr Thomas Olin, CEO, +46 (0)73 520 40 01
Kancera AB (publ)
SE-112 51 Stockholm, Sweden
Visit the company's website at www.kancera.com